The company “expects full-year 2024 product revenue will be in the range of $172M to $175M. Included in this range is full-year 2024 INTERCEPT Fibrinogen Complex revenue guidance between $8M to $10M.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CERS: